<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In Western countries, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) is the most common form of <z:e sem="disease" ids="C0854193" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive deterioration</z:e> after <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Therapeutic trials in VaD have so far failed to yield satisfactory results </plain></SENT>
<SENT sid="2" pm="."><plain>One explanation of this failure may be the etiological and clinical <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of the included patients </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with subcortical VaD, defined on a clinical and radiological basis, may constitute a more homogeneous group </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, we conducted a post-hoc subgroup analysis of the Scandinavian Multi-<z:mpath ids='MPATH_124'>Infarct</z:mpath> <z:hpo ids='HP_0000726'>Dementia</z:hpo> Trial that evaluated the efficacy and safety of oral nimodipine administered for 6 months in 259 patients </plain></SENT>
<SENT sid="5" pm="."><plain>The original patients sample was divided on the basis of head CT in those with subcortical VaD (n=92, 45 nimodipine, 47 placebo) and those with multi-<z:mpath ids='MPATH_124'>infarct</z:mpath> <z:hpo ids='HP_0000726'>dementia</z:hpo> (n=167, 83 nimodipine, 84 placebo) </plain></SENT>
<SENT sid="6" pm="."><plain>While in the total trial population a treatment effect could not be proved, in this subgroup analysis, the subcortical VaD patients treated with nimodipine performed better on the majority of neuropsychological tests and functional scales in comparison with patients on placebo </plain></SENT>
<SENT sid="7" pm="."><plain>No trend could be evidenced in the multi-<z:mpath ids='MPATH_124'>infarct</z:mpath> <z:hpo ids='HP_0000726'>dementia</z:hpo> patients </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment efficacy was in particular suggested for the Zahlen-Verbindungs-Test, Fuld-Object-Memory Evaluation, Word Fluency, and for the Instrumental Activities of Daily Living scale </plain></SENT>
<SENT sid="9" pm="."><plain>The results did not reach statistical significance in this small sample </plain></SENT>
<SENT sid="10" pm="."><plain>Our study preliminarily indicates that nimodipine could be effective in patients with small vessel subcortical VaD and supports the rationale for a further controlled and adequately powered trial to test nimodipine in patients with subcortical VaD </plain></SENT>
</text></document>